Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Tumor × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 62 Hodgkin Disease 46 Lymphoma 18 Sarcoma 10 Neoplasm Metastasis 9 Leiomyosarcoma 7 Skin Neoplasms 6 Neoplasms 5 Uveal Melanoma 4 Recurrence 3 Solitary Fibrous Tumors 2 Sarcoma, Synovial 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Melanoma Neoplasms 1 Lung Neoplasms 1 Liposarcoma 1 Kidney Neoplasms 1

Interventions

pembrolizumab 11 Injections 11 Paclitaxel 10 Docetaxel 9 Cisplatin 8 Nivolumab 7 Capecitabine 7 Bevacizumab 7 toripalimab 6 senaparib 6 atezolizumab 6 Irinotecan 6 tislelizumab 5 Fluorouracil 5 Cyclophosphamide 5 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 Fluorodeoxyglucose F18 4 spartalizumab 3 pertuzumab 3 olaparib 3 fludarabine 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡